307 related articles for article (PubMed ID: 2525113)
21. Opsonization of bacteroides by the alternative complement pathway reconstructed from isolated plasma proteins.
Bjornson AB; Magnafichi PI; Schreiber RD; Bjornson HS
J Exp Med; 1987 Mar; 165(3):777-98. PubMed ID: 3819646
[TBL] [Abstract][Full Text] [Related]
22. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.
Laxalt KA; Kozel TR
Infect Immun; 1979 Nov; 26(2):435-40. PubMed ID: 397927
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
Zaragoza O; Casadevall A
Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
[TBL] [Abstract][Full Text] [Related]
24. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes.
Davies SF; Clifford DP; Hoidal JR; Repine JE
J Infect Dis; 1982 Jun; 145(6):870-4. PubMed ID: 7045251
[TBL] [Abstract][Full Text] [Related]
25. Opsonization of yeast cells with equine iC3b, C3b, and IgG.
Gröndahl G; Johannisson A; Jensen-Waern M; Nilsson Ekdahl K
Vet Immunol Immunopathol; 2001 Aug; 80(3-4):209-23. PubMed ID: 11457475
[TBL] [Abstract][Full Text] [Related]
26. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.
Kozel TR; Weinhold LC; Lupan DM
Infect Immun; 1996 Aug; 64(8):3360-8. PubMed ID: 8757876
[TBL] [Abstract][Full Text] [Related]
27. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
Kozel TR; Gotschlich EC
J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
[TBL] [Abstract][Full Text] [Related]
28. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
[TBL] [Abstract][Full Text] [Related]
29. Alternative pathway of complement.
Pangburn MK
Methods Enzymol; 1988; 162():639-53. PubMed ID: 2976114
[No Abstract] [Full Text] [Related]
30. In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans.
Truelsen K; Young T; Kozel TR
Infect Immun; 1992 Sep; 60(9):3937-9. PubMed ID: 1500204
[TBL] [Abstract][Full Text] [Related]
31. Opsonization and phagocytosis of Cryptococcus neoformans.
Kozel TR
Arch Med Res; 1993; 24(3):211-8. PubMed ID: 8298269
[TBL] [Abstract][Full Text] [Related]
32. Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.
Kozel TR; MacGill RS; Wall KK
Infect Immun; 1998 Apr; 66(4):1547-53. PubMed ID: 9529080
[TBL] [Abstract][Full Text] [Related]
33. [Alternative complement pathway].
Jouvin MH; Kazatchkine M
Sem Hop; 1984 May; 60(19):1371-8. PubMed ID: 6326330
[TBL] [Abstract][Full Text] [Related]
34. [Compliment system proteins: properties and biological activity (Lecture)].
Kashkin KP; Dmitrieva LN
Klin Lab Diagn; 2000 Jul; (7):25-32. PubMed ID: 10981394
[No Abstract] [Full Text] [Related]
35. Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.
Kozel TR; deJong BC; Grinsell MM; MacGill RS; Wall KK
Infect Immun; 1998 Apr; 66(4):1538-46. PubMed ID: 9529079
[TBL] [Abstract][Full Text] [Related]
36. Activation of complement via the alternative pathway.
Pangburn MK
Fed Proc; 1983 Jan; 42(1):139-43. PubMed ID: 6217084
[TBL] [Abstract][Full Text] [Related]
37. Analysis of C3 deposition and degradation on bacterial surfaces after opsonization.
Gordon DL; Rice J; Finlay-Jones JJ; McDonald PJ; Hostetter MK
J Infect Dis; 1988 Apr; 157(4):697-704. PubMed ID: 3279137
[TBL] [Abstract][Full Text] [Related]
38. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
39. Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide.
Kozel TR; Reiss E; Cherniak R
Infect Immun; 1980 Aug; 29(2):295-300. PubMed ID: 7011970
[TBL] [Abstract][Full Text] [Related]
40. In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.
Mershon-Shier KL; Vasuthasawat A; Takahashi K; Morrison SL; Beenhouwer DO
Mol Immunol; 2011 Sep; 48(15-16):2009-18. PubMed ID: 21723612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
